Hans-Peter Schupp
InvestorMale0.0Global Dominance: 0.00%
Hans-Peter Schupp is an investor at the Fidecum fund management company, noted for his analysis of BASF's potential acquisition of Evonik amid a challenging chemical market, highlighting the anticyclical nature of the move.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Hans-Peter Schupp from the Fidecum investment company has invested about 4% of the capital in BASF.
BASF greift nach Evonik und trotzt damit der schlechten ChemiekonjunkturNeue Zürcher Zeitung·
Switzerland· 2026-09-27
Switzerland· 2026-09-27
